Correlation of prostate specific antigen level with histopathological findings in patients with prostatic disease
Abstract
Background: Carcinoma of prostate is one of the common tumors of old age in men. Although there is great apprehension in these patients when they are associated with even mild increase in the prostate specific antigen level (PSA) which can be seen in various benign lesions of prostate. With digital rectal examination (DRE), prostate specific antigen (PSA) remains a major screening tool for early detection of prostate cancer.
Materials and method: The study includes 150 cases who presented clinically as prostatic lesions and in whom the PSA levels and tissue biopsy was available and was further correlated among spectrum of prostatic disease.
Results: All cases with abnormal DRE were turn out to be malignant lesion on biopsy and was found that the cut off of PSA level for malignancy was 19.5ng/ml. The median PSA levels for benign prostatic hyperplasia (BPH), prostatitis, prostate intraepithelial neoplasia (PIN) and adenocarcinoma is 5ng/ml, 10 ng/ml, 14 ng/ml and 81ng/ml respectively. Statistically there was no significant difference of the PSA levels between low grade prostate intraepithelial neoplasm and high grade.
Conclusion: In Benign prostatic lesion, PSA level ranges between 0 to 4.0ng/ml. The cut off value of 19.5ng/ml of PSA is most sensitive and specific for the detection of malignant lesion in the prostate. In addition to elevated level of more than 4.0ng/ml and abnormal DRE with TURP biopsy is most useful and accurate diagnostic method for prostatic lesions. All raised PSA levels cases were not malignant thus it is required to use this biochemical marker judiciously to minimize the apprehension among these patients.
Downloads
References
2. Brawer MK. Screening and early detection of prostate cancer will decrease morbidity and mortality from prostate cancer. The Augment for Eur Urol. 1996; 29(2):19–23.
3. A. Amayo and W.Obara. Serum prostate specific antigen levels in men with benign prostatic hyperplasia and cancer of prostate. East African Medical Journal 2004; 81(1):22-25.
4. Lakhey.M,Ghimire. R,Shrestha .R,Bhatta A D.Correlation of serum free prostate- specific antigen level with histological findings in patients with prostatic disease. Kathmandu University Medical Journal 2010; 8(30):158-163.
5. Jasmin H Jasani, Himani B. Patel, Bijol Gheewala, Hetal V. Vaishnani, Kaushik Bhuva. Diagnostic utility of prostate specific antigen for detection of prostatic lesions. International Journal of biomedical and advance research 2012; 3(4):268 – 272.
6. Goswami A, Rupala G et al. Serum PSA levels in prostatic lesions with histopathological correlation in Gujarat. NJIRM 2011; 2(4):33-38.
7. Lowe FC et al. Risk factors for disease progression in patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH): a systematic analysis of expert opinion. Prostate Cancer and Prostatic Diseases 2005; 8:206–209. doi:10.1038/sj.pcan.4500806. [PubMed]
8. Jimenez-Cruz F. Identifying patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH) at risk for progression. Eur Urol Suppl 2003; 2: 6–12.
9. DP Murthy, U Ray, J Morewaya, SK Sengupta. A study of the correlation of prostatic pathology and serum prostate specific antigen levels; A perspective from Papua New Guinea. PNG Med J. 1998; 41(2):59–64.
10. Cavit C, Tanner C et al. Correlation of serum free/total prostate specific antigen (PSA) levels with histological findings in the Turkish men with prostatic disease after the first biopsy. Scholarly Journal of Medicine 2011; 1(1): 5-11.
11. Kshitij A. jyoti sapre, A.S.Agnihotri et al: utility of prostate specific antigen in different prostatic lesion: Pathology and laboratory medicine; Jun 2011 ;( 1): 18-23.
12. Khan I A et al. Carcinoma of prostate in clinically benign enlarged gland. J Ayub med coll Abottabad 2008; 20(2): 90-92. [PubMed]
13. Yamamoto M, Hibi H, Miyake K. Prostate specific antigen levels in acute and chronic bacterial prostatitis. Acta Urol.Jpn 1993; 39:445 – 449. [PubMed]
14. Brawer MK, Lange PH. Prostate-Specific Antigen and Premalignant Change: Implications for Early Detection. CA: A Cancer journal for clinicians 1989; 39(6):361 – 375.
15. Brawer MK, Porter JR.Prostatic intraepithelial neoplasia and prostate specific Antigen. World J Urol 1993; 11(4):196 – 200. [PubMed]
16. Abukult O N, Duman I. Prostatic intraepithelial neoplasm: Retrospective results of Clinical, histopathological approaches. Journal of Cell and Molecular Biology 2004; 3:45 – 50.
17. Obralic N, Kulovac B. High grade intraepithelial neoplasia of prostate is associated with values of prostate specific antigen related parameters intermediate between prostate cancer and normal levels. Bosn J Basic Med Sci 2011; 11(4): 223-227.
18. KIM H. L, Yang X. Prevalence of High-Grade Prostatic Intraepithelial Neoplasia and its relationship to serum prostate specific antigen. International Braz J Urol 2002; 28(5):413 – 417.
19. Bretton, P.R. Prostate-specific antigen and digital rectal examination in screening for prostate cancer: a community-based study. South Med J 1994; 87(7):720 – 723.
20. Richie J.P, Catalona W. Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. Urology1993; 42(4):365-74.
OAI - Open Archives Initiative
